Hypoxia News and Research RSS Feed - Hypoxia News and Research

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.
Recipients of GSA poster awards announced at 20th International C. elegans Meeting

Recipients of GSA poster awards announced at 20th International C. elegans Meeting

The Genetics Society of America and the C. elegans research community are pleased to announce the recipients of the GSA poster awards at the 20th International C. elegans Meeting, which took place at the University of California, Los Angeles, June 24-28, 2015. [More]
UC San Diego researchers identify pivotal player in diabetic kidney disease

UC San Diego researchers identify pivotal player in diabetic kidney disease

Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease. [More]
ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital. [More]
Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics. [More]
New 'smart insulin patch' could help patients suffering from diabetes

New 'smart insulin patch' could help patients suffering from diabetes

Painful insulin injections could become a thing of the past for the millions of Americans who suffer from diabetes, thanks to a new invention from researchers at the University of North Carolina and NC State, who have created the first "smart insulin patch" that can detect increases in blood sugar levels and secrete doses of insulin into the bloodstream whenever needed. [More]
UT Southwestern scientists devise new technique to identify cell that replenishes adult heart muscle

UT Southwestern scientists devise new technique to identify cell that replenishes adult heart muscle

Regenerative medicine researchers at UT Southwestern Medical Center have identified a cell that replenishes adult heart muscle by using a new cell lineage-tracing technique they devised. [More]
Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Scientists forecast an average 'dead zone' in Gulf of Mexico this year

Scientists forecast an average 'dead zone' in Gulf of Mexico this year

Scientists are expecting that this year's Gulf of Mexico hypoxic zone, also called the "dead zone," will be approximately 5,483 square miles or about the size of Connecticut-the same as it has averaged over the last several years. [More]
La Jolla Institute researchers identify molecular pathway that maintains Treg cells' function

La Jolla Institute researchers identify molecular pathway that maintains Treg cells' function

Regulatory T cells (Treg cells) are part of the system of checks and balances that prevents the immune response from going overboard and causing autoimmune disease. Although critically important for shaping the immune response and maintaining self-tolerance, how they hold on to their immune-suppressive powers had remained unclear. [More]
Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States. [More]
Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

Adding AKT inhibitors to radiotherapy could be effective for treating many cancers

Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today. [More]
Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. [More]
Immune system plays surprising role in the progression of Rett syndrome

Immune system plays surprising role in the progression of Rett syndrome

New research by investigators at the University of Massachusetts Medical School suggests the immune system plays an unsuspected and surprising role in the progression of Rett syndrome, a severe neurological disorder affecting children. Immune cells known as macrophages are unable to perform their normal function and are instead amplifying the disease. [More]
Researchers study early response of cells to ischemia

Researchers study early response of cells to ischemia

A group of researchers from the Lomonosov Moscow State University in collaboration with their Irish colleagues from the University College Cork has studied the early response of cells to ischemia, which is a restriction in blood supply to tissues causing the death of the cell. [More]
TSRI study provides new insight into preventing diseases that cause vision loss in adults

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Insulin signaling pathway has significant influence on the growth of glioblastomas

Insulin signaling pathway has significant influence on the growth of glioblastomas

Drugs that target insulin pathways to slow or stop the growth of brain tumors are going in the right direction but appear to be on the wrong track, according to new research at Rice University. [More]
Latest findings regarding nitric oxide offer new avenues to save lives

Latest findings regarding nitric oxide offer new avenues to save lives

Professor Jonathan Stamler's latest findings regarding nitric oxide have the potential to reshape fundamentally the way we think about the respiratory system - and offer new avenues to save lives. It may be time to rewrite the textbooks. [More]
Prevalence of ADHD decreases substantially as altitude increases

Prevalence of ADHD decreases substantially as altitude increases

Recent research has linked the thin air of higher elevations to increased rates of depression and suicide. But a new study shows there's also good news from up in the aspens and pines: The prevalence of attention deficit hyperactivity disorder (ADHD) decreases substantially as altitude increases. [More]
Advertisement
Advertisement